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a b s t r a c t
Studies in cattle show CD8 cytotoxic T cells (CTL), with the ability to kill intracellular bacteria, develop
following stimulation of monocyte-depleted peripheral blood mononuclear cells (mdPBMC) with antigen
presenting cells (APC, i.e. conventional dendritic cells [cDC] and monocyte-derived DC [MoDC]) pulsed
with MMP, a membrane protein from Mycobacterium avium subsp. paratuberculosis (Map) encoded by
MAP2121c. CTL activity was diminished if CD4 T cells were depleted from mdPBMC before antigen (Ag)
presentation by APC, suggesting simultaneous cognate recognition of MMP epitopes presented by MHC
I and MHC II molecules to CD4 and CD8 T cells is essential for development of CTL activity. To explore
this possibility, studies were conducted with mdPBMC cultures in the presence of monoclonal antibodies
(mAbs) specific for MHC class I and MHC class II molecules. The CTL response of mdPBMC to MMP-pulsed
APC was completely blocked in the presence of mAbs to both MHC I and II molecules and also blocked in
the presence of mAbs to either MHC I or MHC II alone. The results demonstrate simultaneous cognate
recognition of Ag by CD4 and CD8 T cells is essential for delivery of CD4 T cell help to CD8 T cells to elicit
development of CTL.
 2019 Elsevier Ltd. All rights reserved.
1. Introduction
Mycobacterium avium subspecies paratuberculosis (Map) is a
higher-order bacterial pathogen with a broad host range that
includes livestock and humans [1,2]. Similar to M. tuberculosis
and M. bovis, initial infection leads to development of a persistent
infection under immune control. In some cases, immune control
may become compromised, leading to granulomatous ileitis, mal-
absorption, wasting, and death [3].
Paratuberculosis (Ptb), also referred to as Johne’s disease (JD) in
ruminants, is a significant causeof livestockmorbidity andmortality
worldwide. The increased incidence of Map infection in ruminants
has been accompanied by an increased prevalence ofMap infection
in humans. Some infected individuals have developed granuloma-
tous ileitis similar to that observed in JD-infected ruminants. Inter-
estingly, the lesions and the resultant intestinal illness are often
observed in patients with Crohn’s disease (CD) [2,4,5], and Map
has been cultured from numerous patients with CD. Such observa-
tions have increased interest in developing methods to limit Map
infection in livestock, thereby reducing the risk for humanexposure.
https://doi.org/10.1016/j.vaccine.2019.12.052
0264-410X/ 2019 Elsevier Ltd. All rights reserved.
Abbreviations: mdPBMC, monocyte-depleted peripheral blood mononuclear
cells; cDC, conventional dendritic cells; MoDC, monocyte-derived DC; MoMU,
monocyte-derived macrophages; Map, Mycobacterium avium subsp. paratuberculo-
sis; WT, wild type; MMP, 35 kDa membrane peptide; PMA, Propidium monoazide;
qPCR, quantitative PCR; CT, cycle threshold.⇑ Corresponding author.
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With this objective in mind, we developed a candidate peptide-
based vaccine for Map that elicits development of CD8 cytotoxic T
cells capable of killing intracellular bacteria [6,7]. Following inocu-
lation with wild type (WT) Map or Map deletion mutants (Map/
DrelA or Map/DpknG [8,9]), calves develop both CD4 and CD8 T-
cell proliferative responses to Map soluble antigens and Johnin
(purified protein derivative, PPD made from Map), both before
and after subsequent challenge with Map [10]. Of interest, only
the Map/DrelA mutant was unable to establish a persistent infec-
tion. In addition, calves inoculated with Map/DrelA exhibited
reduced colonization by WT Map on subsequent challenge. These
data indicated a difference in the immune response of calves to
Map/DrelA as compared to that elicited by WT Map [10].
The immune response of a steer inoculated withMap/DrelA was
evaluated in an attempt to understand why this mutant could not
establish a persistent infection. PBMC from the steer were pulsed
with liveMap/DrelA to examine the recall response [11]. Initial stud-
ies showed stimulation of the steer’s PBMC withMap/DrelA elicited
a proliferative CD4 and CD8 T cell recall response. Analysis of effec-
tor activity revealed that the responding CD8 T cells were cytotoxic,
killing intracellular bacteria [6]. Minimal induction of cytotoxic
activity was detected in the responding CD4 T cell population. Fur-
ther analysis of the recall immune response to Map/DrelA revealed
the target of the response was a 35 kDa membrane peptide, MMP,
encoded by MAP2121c [11,12]. An identical CTL recall response
was elicited when PBMC were pulsed with Map/DrelA or MMP [6].
The recall responses to Map/DrelA and MMP were blocked in the
presence of monoclonal antibodies (mAbs) specific for MHC class I
and II molecules, verifying that the CD4 and CD8 T-cell recall
responses were MHC restricted. Although in retrospect, studies
should have included examination of the effect of antibodies to
MHC I alone and MHC II alone, they were not included.
Further investigation using blood from Map unexposed steers
revealed the same CTL response could be elicited entirely ex vivo
by using two rounds of stimulation of monocyte depleted PBMC
(mdPBMC) with APC pulsed with MMP [6]. The proliferative and
CTL responses were reduced if either CD4 or CD8 T cells were
depleted from mdPBMC before culture with APC pulsed with
MMP. This finding suggested CD4 and CD8 T cells had to recognize
their respective antigenic epitopes, presented by APC in context of
MHC I and MHCII molecules, at the same time for development of
CTL. The present study was conducted to explore this possibility in
greater detail. As reported, the data provide evidence showing
MMP is taken up by APC (cDC and MoDC) via the exogenous route
and processed for Ag presentation by MHC class I and MHC class II
molecules. The proliferative and CTL responses were blocked in the
presence of antibodies to both MHC I or MHC II as observed in
studies of the recall response [6]. The responses were also blocked
in the presence of antibody to MHC I alone and also to MHC II
alone. This finding provides evidence that CD4 and CD8 T cells
must recognize their respective antigens at the same time for
development of CTL. Of importance to investigations on develop-
ment of vaccines, the results answer a longstanding question.
How and when is CD4 T cell help delivered to CD8 T cells to elicit
development of CD8 cytotoxic T cells?
2. Material and methods
2.1. Animals
Three Holstein steers were obtained from the Map-free Wash-
ington State University (WSU) dairy herd in 2017. The steers were
kept in an open feed lot and used as a source of blood to conduct
the ex vivo studies on the immune response to MMP. Steers were
maintained by the WSU animal care staff, and all protocols were
approved by the WSU Institutional Animal Care and Use Commit-
tee (ASAFs 3360 and 04883).
2.2. Preparation of MMP and Map K10
The full length MMP used for antigen presentation by antigen
presenting cells (APC) is encoded byMAP2121c in the K-10 genome
[12,13]. It was expressed in ClearColi as a maltose-binding protein
fusion for purification [14]. Cultures of Map K10 were prepared
from single colonies and used to inoculate Middlebrook 7H9 broth
flasks (Difco, BD biosciences, USA) supplemented with 6.7% para-
JEM GS (Trek Diagnostic Systems, OH), 2 lg/mL mycobactin J
(Allied Monitor, MO, USA), and 0.05% Tween 80 (Sigma-Aldrich
Corp.) [10,15]. The cultures were expanded on a shaking stand at
37 C. When the broth cultures reached an OD600 of 0.6 to 0.8,
master stocks were prepared in 1.5 mL micro-centrifuge screw-
cap tubes for immediate use in each experiment. To ensure a
single-cell suspension, bacterial stocks were disaggregated by pas-
sages through a 26-gauge needle three times, and bacterial num-
bers were estimated based on the final OD600 values [15].
2.3. Blood processing for cell separation and culture
The flow diagram in Fig. 1 illustrates the protocols used to con-
duct studies with cells obtained from the three Map-negative Hol-
stein steers. As illustrated in Fig. 1, peripheral blood mononuclear
cells (PBMC)werepreparedbydensity gradient centrifugationusing
Ficoll- Hypaque (0.077). One portion of the PBMC was used to gen-
erate MoMU for use in the viability assay as described below. The
second PBMC portion was labelled with magnetic microbeads
coatedwith a cross-reactive anti-humanCD14mAb to isolatemono-
cytes per themanufacturer’s instructions (Miltenyi Biotec) [16]. The
averagepurity of isolatedCD14+ cellswas greater than98%, as deter-
mined by FC analysis using an anti-bovine CD14 mAb, CAM36A
[17,18]. Monocytes (2 106) were added to wells of six well culture
plates and cultured in 3 mL of complete culture medium (cRPMI)
[RPMI-1640mediumwith GlutaMAXTM (Life Technologies, CA) sup-
plemented with 10% calf bovine serum (CBS), 1 mM b-
mercaptoethanol, 100 units/mL of penicillin G, and 100 lg/mL of
streptomycin sulfate] in the presence of a DC growth cocktail con-
taining bovine GM-CSF and IL-4 (Kingfisher Biotech, MN). On the
third day, 1.4 mL of the medium was replaced with 1.8 mL of fresh
medium containing the cocktail. The cultures were incubated for
an additional three days to obtain MoDC.
The mdPBMC were initially incubated for 30 min at 37 C, 5%
CO2 with the following combinations of the primary mAbs with
no azide (1 lg each/ 106 cells): Anti-CD8 and anti- cd T cells;
Anti-CD4 and anti- cd T cells; and anti- cd T cells. After incubation,
cells were washed three times with warm RPMI to remove
unbound antibodies.
The three sets of primary mAb-treated mdPBMC were then
incubated for 15 min at 4 C with anti-mouse IgG2a + b microbeads
per the manufacturer’s instructions (Miltenyi Biotec). After incuba-
tion, the cells were washed two times with cold MACS buffer (a
solution containing phosphate- buffered saline (PBS), pH 7.2, 0.5%
bovine serum albumin (BSA), and 2 mM EDTA) to remove the
unbound microbeads, and then re-suspended in the same buffer.
For magnetic separation, LS columns were placed in the magnetic
field of a MACS Separator and rinsed with 3 mL of MACS buffer,
and cell suspensions were loaded onto the wet columns. Flow-
through containing the following three unlabeled cell fractions of
mdPBMC were collected (negative selection): CD4 T cells, CD8 T
cells and CD4/CD8 T cells. Unseparated mdPBMC were also main-
tained for use as positive and negative control wells.
The three mdPBMC fractions and unseparated mdPBMC were
subjected to two rounds of antigenic stimulation using MMP. To
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conduct the first round of stimulation, cells were distributed in the
6-well culture plate in duplicate (2  106/mL in 5 mL of cRPMI).
MMP (5 lg/mL) was added to each well and incubated for 6 days
at 37 C, 5% CO2 to allow MMP processing and presentation by
cDC present in the mdPBMC. To conduct the second round of stim-
ulation after 6 days of culture,MMP (5lg/mL)was added to the cul-
tures of MoDC and incubated for 3 h at 37 C, 5% CO2. The adherent
MoDC were then carefully washed 3 times with warm RPMI to
remove the cell-free MMP. The primed cells were collected, washed
twice with warm RPMI, and added to their respective autologous
MoDC pulsed with MMP (2  106/mL in 5 mL of cRPMI). After six
additional days of culture, the cells were collected and used in FC
and the Map viability assay as described below. A portion of the
unseparated mdPBMC was maintained as a negative control with
no antigen stimulation during the two weeks of cell culture.
2.4. Viability assay
Control and antigen-stimulated mdPBMC and CD4 T-cell, CD8
T-cell, and CD4/CD8 T-cell fractions were used as effector CTLs in
the viability assay.
2.4.1. Generation of MoMU for use as target cells
As mentioned above, one portion of fresh PBMC was re-
suspended in cRPMI transferred into 150 mm tissue culture plates
and incubated overnight. The majority of the non-adherent cells
were then removed the following day. The adherent cells were cul-
tured in fresh medium for six days then brought into suspension by
incubation on ice in the presence of EDTA in PBS (4 mL EDTA
[250 mM stock in H2O], 5 mL CBS, 91 mL PBS). The MoMU were
distributed into six well culture plates (2  106 cells/ well) and cul-
tured for an additional six days, and then used as target cells in the
viability assay.
2.4.2. Infection of target cells with Map K10
MoMUwere infected withMap K10 at a multiplicity of infection
(MOI) of 10:1 (2  107 Map to ~ 2  106 MoMU/well) in antibiotic-
free cRPMI. Culture plates were centrifuged at 700g for five min-
utes, then incubated at 37 C, 5% CO2 for 3 h. Extracellular bacteria
were removed by washing five times with warm, antibiotic-free
RPMI using gentle suction to avoid detaching adherent MoMU.
Two wells from each of the respective sets of 6 wells, containing
Fig. 1. Flow diagram illustrating preparation of mdPBMC for analysis of the immune response to MMP ex vivo. See methods for detail.
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Map infected MoMU, were used as controls, without addition of
primed or unprimed preparations of mdPBMC.
2.4.3. Incubation of effector T cells with infected target cells
Stimulated and control mdPBMC and T-cell fractions were col-
lected and added to the preparations of infected MoMU. Co-
cultures were incubated for 24 h at 37 C, 5% CO2. Non-adherent
cells were collected, then adherent cells were detached and col-
lected as described above. Finally, collected adherent and non-
adherent cells were recombined for analysis of Map viability.
2.4.4. Cell lysis
Following collection, cells were lysed by adding 2 mL of 0.01%
saponin in H2O and incubated at 37 C for 15 min. The cell lysates
were centrifuged for 30 min at 4500 rpm to pellet the bacteria. The
supernatants were discarded and the pellets re-suspended in 1 mL
H2O and transferred into micro-centrifuge tubes, then centrifuged
at 14,000 rpm for 10 min. The supernatants were discarded, and
the pellets re-suspended in 400 lg of H2O in 1.5 mL translucent
Eppendorf tubes and stored at 20 C until used.
A set of controls was prepared from known mixtures of live and
dead Map K10. This set of controls covered the dynamic range for
detection of live vs deadMap obtained from infected MoMU before
and after incubation with CTL. Aliquots of Map mixed in five ratios,
100% live, 75% live/25% killed, 50% live/50% killed, 25% live/75%
killed, and 100% killed, were prepared to obtain 2  107 total
Map in each aliquot, added to the cultures of MoMU at a MOI of
10, and incubated for 3 h as described previously [6]. The cultures
were then washed to remove free bacteria. Adherent cells were
collected and transferred into new 15 mL tubes. 107 fresh mdPBMC
were added for each tube and all the cells were mixed followed by
centrifugation. The cell pellet in each tube was lysed with saponin
as described above, and lysates stored at 20 C until use.
2.4.5. PMA treatment, DNA extraction and qPCR
Propidium monoazide (PMA) treatment of the cell lysates was
carried out as previously described [6]. Briefly, 1 mL of 20 mM
PMA working stock solution was added to 400 mL of each previ-
ously prepared cell lysates to reach a final dye concentration of
50 mM. The translucent PMA-treated tubes were incubated at room
temperature for five minutes in the dark on a rocker. The tubes
were then placed in a plastic tray prepared with a frozen ice pack
wrapped in aluminum foil. The tray was then placed on a rocking
platform to ensure continuous mixing during light exposure. Light
exposure was performed for five minutes using a halogen lamp
with a 650 W bulb placed at a distance of ~20 cm from the tubes.
Cells were subsequently harvested by centrifugation at 10,000g for
five minutes. Supernatants were discarded, and the cell pellets pro-
cessed for DNA isolation [19].
DNA extraction was performed according to the protocol for
Gram-positive bacteria using DNeasy Blood and Tissue kit (Qia-
gen, USA) following enzymatic lysis to facilitate breakdown of
the Map cell wall as described by Park et al. [19]. TaqMan Quanti-
tative Real-Time PCR, targeting the single copy F57 gene specific
for Map (F57 qRT-PCR) was used to determine the activity of intra-
cellular Map killing as described by Kralik et al. [20] and Abdell-
razeq et al. [6]. The reaction was performed according to
Schönenbrücher et al. [21] using a StepOnePlus Real-Time PCR
machine (Applied Biosystems, CA). Map gDNA prepared from pure
culture was used to generate a standard curve with the F57 probe,
made with 8 dilutions starting with 4  107 copies down to 4
copies. The sequences of the primers and probes were the same
as previously described [19]. The total reaction volume was
25 lL including 5 lL of the DNA sample, and reactions were run
for 40 cycles. The mean values of the cycle threshold (CT) were ana-
lyzed using StepOne Software v2.1 (Applied Biosystems, CA).
2.5. MHC blocking
Four identical sets of unseparated mdPBMC cultures were pre-
pared for the comparative study. One set was used as a control
with no antibody added. One set was incubated with both MHC I
and MHC II (0.5 lg/ml) and one each with either antibody to
MHC I or MHC II. In addition, one culture was prepared and cul-
tured with an isotype control antibody to verify mAbs specific for
other antigens have no effect on the proliferative response to
MMP (Table 1). Cultures were subjected to two rounds of stimula-
tion with MMP as described above, and cell activation and prolifer-
ation assessed using FC. The resultant cultures of cells were then
incubated with infected MoMU for 24 h. The cells were collected
and processed to determine the CTL activity in each preparation
of cells using the bacterium viability assay as described.
2.6. Flow cytometric analysis
After the second round of antigen stimulation, cells were
washed once in PBS/ACD, centrifuged, re-suspended in serum-
free RPMI and counted. For antibody labeling, cells were dis-
tributed into 96-well polystyrene V-bottom microplates (106
cells/well). Combinations of mAbs (Table 1) obtained from the
WSU Monoclonal Antibody Center (WSUMAC) were used for label-
ing as previously described [22]. Data were collected on a modified
FACS Calibur DxP8 Analyzer equipped with a FlowJo operating sys-
tem (Cytek Biosciences Inc. Fremont, CA) and analyzed with FCS
Express software (DeNovo Software, Glendale, CA) [17]. The gating
strategy used to collect the data is shown in Fig. 2. Side scatter
(SSC) and forward scatter (FSC) were used to identify small and
large lymphocytes. FSC-Height vs FSC-Width (FSC-H vs FSC-W)
was used to exclude doublets. Selective electronic gating was used
to isolate CD4 and CD8 T cells for determination of their activation
status.
2.7. Statistical methods
Data were imported into SAS software (SAS for Windows, ver-
sion 9.3) for statistical analysis and graphical presentation. The
data were analyzed using a mixed modeling procedure (PROC
GLIMMIX). For proportional response data (proportion activated
T cells), statistical models included the main fixed effects of
MMP stimulation (MMP, diluent control) and T cell type (CD4,
CD8), the interaction term of these effects, and was based on the
binomial response distribution and Kenward-Roger degrees of
freedom approximation. These experiments were considered to
be of heirarchical design; the corresponding statistical models thus
included random residuals defined by T cell types nested within
each subject (blood donor steer), and an unstructured (Cholesky)
Table 1










H58A IgG2a MHC I
PT85A IgG2a MHC I
TH14B IgG2a MHC II BoLA DR
TH81A5 IgG2a MHC II BoLA DQ
CAT82A IgG1 MHC II
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covariance matrix. Multiple comparisons were adjusted using the
method of Holm-Tukey (overall a = 0.05).
For CT response data (qPCR estimation of intracellular Map kill-
ing), statistical models included the single main fixed effect of
manipulating the mdPBMC context of MMP stimulation (manipu-
lation of T cell context or manipulation of MHC I and II context,
each with controls). These analyses were based on the Poisson
response distribution and Kenward-Roger degrees of freedom
approximation, and included a random effect of residuals defined
by subjects and using the default variance component structure
of the covariance matrix. Under these experimental scenarios, only
comparisons of interest were made utilizing the Dunnett method
of adjustment for multiple comparisons (overall a = 0.05).
3. Results
3.1. The proliferative response of mdPBMC is reduced if either CD4 or
CD8 T cells are depleted before stimulation with MMP
The experiments were conducted to verify and gain further
insight into the effect of CD4 and CD8 depletion on CTL develop-
ment following MMP stimulation. Negative selection was used to
deplete either CD4 or CD8 T cells from mdPBMC. The depletion
strategy included use of a mAb to the d chain of the cd TCR to
exclude any potential effect of cd T cells on the proliferative
response to MMP. Previous studies established that NK cells do
not contribute to the proliferative response to MMP [6]. Little dif-
ference could be detected between the untreated positive control
preparation of mdPBMC and preparations depleted of either CD4
or CD8 T cells after one round of stimulation with MMP (not
shown). However, clear differences were evident after two rounds
of stimulation (Fig. 3).
mdPBMC incubated with MMP had significantly larger
(FMMP = 168.06, P = 0.0002) proportions of activated CD4 T cells
(Padj = 0.0005) and activated CD8+ T cells (Padj = 0.0013) than
mdPBMC incubated without MMP. Significant differences were
not detected between the proportions of activated CD4 and CD8
T cells within the mdPBMC (FCD = 0.7277, P = 0.7277) nor in the
change induced by MMP (FMMP*CD = 2.61, P = 0.1816).
The cellular context during incubation with MMP did have a
significant effect on the proportions of activated T cells (FCon-
text = 44.68, P = 0.0053). Post-hoc comparisons were limited to
within each cell type since the effects on the two phenotypes of
T cells were parallel (see Fig. 3) and only marginally different in
magnitude (FContext*CD = 13.23, P = 0.0308). The proportion of acti-
vated CD4 T cells in mdPBMC depleted of both CD8 T cells and cd T
cells was significantly less than the proportions present in whole
mdPBMC (Padj = 0.0327) and mdPBMC depleted of only cd T cells
(Padj = 0.0225). The proportion of activated CD4 T cells in mdPBMC
depleted of cd T cells was not significantly different than that in
whole mdPBMC (Padj = 0.0542).
Similarly, the proportion of activated CD8 T cells in mdPBMC
depleted of both CD4 T cells and cd T cells was significantly less
than the proportions within whole mdPBMC (Padj = 0.0131) and
mdPBMC depleted of only cd T cells (Padj = 0.0022). The proportion
of activated CD8 T cells in mdPBMC depleted of only cd T-cells was
not significantly different than that in whole mdPBMC
(Padj = 0.0786).
3.2. The CTL activity of mdPBMC is reduced if either CD4 or CD8 T cells
are depleted before stimulation with MMP
In conjunction with experiments to investigate the effects of T-
cell depletion on the proliferative response to MMP, one set of cell
preparations was used to determine the effects of depletion on CTL
activity against intracellular Map in target MoMU (Fig. 4). Manip-
ulation of cellular context did significantly affect killing of intracel-
lular bacteria (as estimated by CT; F = 16.40, P < 0.0001). Fig. 4
depicts the outcomes of this experiment relative to a standardized
scale of intracellular killing whereas statistical comparisons to the
maximal killing produced by whole mdPBMC 24-hours post stim-
ulation with MMP are shown in Fig. 5. The intracellular killing of
Map in MoMU co-cultured with MMP-stimulated whole mdPBMC
was significantly greater than the control conditions (vs. MoMU at
0-hours and at 24-hours post-stimulation, each Padj < 0.0001; vs.
MoMU -control at 24-hours post-stimulation, Padj = 0.0005). A sig-
nificant reduction in intracellular killing of Map was not detected
when only cd T-cells were depleted from mdPBMC prior to MMP
stimulation (Padj = 0.4682), but was detected with the additional
depletion of CD4 T cells (Padj = 0.0457) or CD8 T cells (Padj = 0.0089).
3.3. Development of CD8 CTL to Map is inhibited by mAb blockade of
MHC class I and/or class II molecules
Depletion experiments confirmed the requirement of both CD4
and CD8 T cells during priming by DC for the generation of signif-
icant anti-Map CTL activity ex vivo. However, depletion experi-
ments did not reveal whether development of CTL activity
required cognate recognition of MMP epitopes presented on APC
MHC I and MHC II molecules by CD4 and CD8 T cells during anti-
genic stimulation. Our previous studies of the recall response to
Map/DrelA and MMP revealed the recall response was blocked in
the presence of mAbs to both MHC I and MHC II molecules [11],
but the effect of individual MHC class I or class II molecule block-
ade was not investigated. To complete the last set of experiments
in this study, mdPBMC were stimulated with MMP in the presence
of mAbs specific for either or both MHC I and MHC II molecules
(Table 1). To maintain consistency with the initial studies, two
Fig. 2. Flow cytometric gating strategy. Gates were used to isolate CD4 and CD8 T cell subsets for analysis of their proliferative response following stimulation with cDC and
MoDC pulsed with MMP. (A) Two light scatter parameters, side scatter (SSC) vs forward scatter (FSC) were used to identify the small lymphocytes (G1, color coded red) and
large activated lymphocytes (G2, color coded blue) based on size and granularity. (B) A pulse geometry gate (FSC-H vs FSC-W) was placed on single cells (G3) to exclude
doublets. (C) A fourth gate (G4) was used to isolate CD4 and CD8 T cells to determine their activation status. For data analysis, FSC vs CD45R0 (a memory T cell marker) was
used to distinguish non-activated memory cells (red) from activated memory cells (blue) proliferating in response to stimulation with MMP. (D) Only the activated memory
cells (upper right quadrant in the dot plot) were considered for statistical analysis. (For interpretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
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mAbs were used for MHC I blockade and two mAbs (one specific
for the bovine orthologue of HLA-DR, one specific for the bovine
orthologue of HLA-DQ) were used for MHC II blockade. Comparison
of the effect of an isotype control antibody, on the proliferative
response to MMP with a culture of mdPBMC with no treatment,
showed there was no nonspecific inhibitory effect on the prolifer-
ative response to MMP (Fig. 6A). However, the effect of MHC mole-
cule blockade on cell proliferation and the development of CTL
activity against intracellular Map was significant (F = 29.05,
P < 0.0001). The intracellular killing of Map by CTL in whole
mdPBMC was significantly greater (all Padj < 0.0001) than the neg-
ative control conditions and to that observed in cultures containing
mAbs to either MHC I or MHC II molecules as well as in the pres-
ence of both MHC I and MHC II mAbs (Fig. 6B).
4. Discussion
Extensive studies have been conducted to elucidate the mecha-
nisms regulating development of CD8 CTL activity against viral and
bacterial pathogens, intracellular parasites, and cancers with the
long-term objective of vaccine development. Cumulative studies
have shown DC play a central role in stimulating CTL activity
through cross presentation of antigenic epitopes presented in con-
text of MHC I molecules (reviewed in [23,24]). What has not been
fully explained in these studies is the role of CD4 T cells in the
development of CD8 CTL activity. Indeed, reports on the role of
CD4 T cell help seems to vary greatly between different model sys-
tems. Development of the primary CTL response to highly inflam-
matory targets, such as whole organism or bacterial membrane-
based vaccines, are reported to be CD4 T cell independent
[25,26], while CD4 T cell help during priming are reported to be
necessary for the development of a functional memory CTL
response to these antigens [27–30]. CD4 T-cell help has also been
reported to be necessary for activation of the CTL recall response.
In contrast, the generation of both primary and recall CD8 CTL
responses to poorly antigenic targets, including peptide immuno-
gens and neoplastic cells, have been reported to require CD4 T cell
help during priming and recall responses [31,32].
The mechanism of action of CD4 T cell help in these systems has
not been clearly elucidated. Some studies have suggested CD4 T
cells may play an indirect role and that interaction of CD154
(expressed on CD8 T cells) with CD40 (expressed on APC) might
be the triggering event that initiates the primary activation and
secondary expansion of CD8 T cells (reviewed in [33–35]). Results
from other studies have suggested that cognate recognition of anti-
gens presented in the context of DC MHC class II and class I mole-
cules, coupled with subsequent stimulation by DC through
ancillary receptor-ligand interactions, are key steps in priming
CTL responses [36,37]. Although complex inbred mouse models
have provided insight into the events associated with the genera-
tion of CTL in vivo, additional information is still needed to fully
detail the events regulating development of CTL responses in out-
bred species, like cattle and humans. The present studies were con-
ducted using an outbred bovine model system to characterize the
CTL response to a candidate Map peptide-based vaccine.
Key to the development of our model system was the finding
that CD209 is uniquely expressed on cDC in blood and MoDC in
cattle [11]. Due to the size of cattle, access to large volumes of
Fig. 3. The role of cellular context on CD4 and CD8 T cell activation by MMP. Two-rounds of stimulation of unseparated mdPBMC (all mdPBMC) with MMP increased the
percentages of activated CD4 T cells and CD8 T cells (control vs MMP). The percentages of activated CD4 T cells and CD8 T cells after stimulation were not significantly
reduced if the mdPBMC were first depleted of cd T cells (cellular context: CD4/CD8 T cells versus all mdPBMC). The percentage of activated CD4 T cells after stimulation was
reduced if the mdPBMC were depleted of cd T cells and CD8 T cells (CD4 T cells versus all mdPBMC, and versus CD4/CD8 T cells). The percentage of activated CD8 T cells after
stimulation was similarly reduced if the mdPBMC were first depleted of cd T cells and CD4 T cells (CD8 T cells versus all mdPBMC, and versus CD4/CD8 T cells). Data shown
are the least squares means and standard deviations for experiments on blood collected from 3 steers. Significance symbols represent P-values adjusted for all pairwise
comparisons such that: *, Padj < 0.05; **, Padj < 0.01; ***, Padj < 0.001.
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blood obviated the difficulty in obtaining sufficient quantities of
cDC for comparative studies with MoDC [11]. The development
of a bovine DC-lymphocyte culture system enabled dissection of
primary and recall CTL immune responses to antigenic peptides
presented in context of MHC I and MHC II molecules under defined
conditions. TheMap/DrelAmajor membrane protein antigen, MMP,
provided a model peptide antigen to study factors affecting devel-
opment of CTL to a candidate peptide vaccine. Finally, development
Fig. 4. The role of cellular context during stimulation by MMP on intracellular killing of Map. Illustration of data presented on a representative standard DNA curve. The
number of live bacteria were estimated by qPCR (CT values). Standards of live:deadMap bacteria are labelled above the data (blue connectors). Note that the relationship of CT
values with live bacterial content (log of F57 quantity) is inverse and linear within the effect range of interest. Experiment test conditions (MMP stimulation and cellular
context of mdPBMC) are noted below the data (independently colored shapes). (For interpretation of the references to color in this figure legend, the reader is referred to the
web version of this article.)
Fig. 5. Cumulative CT values of intracellular killing of Map. In comparison to control conditions (left most solid bars), significant killing of Map (reduced live bacteria = higher
value) was detected after infected MoMU were co-cultured 24-hours with unseparated mdPBMC stimulated by MMP (open bar). Manipulation of cellular context during
stimulation of mdPBMC with MMP (rightmost solid bars) did not significantly reduce intracellular killing with depletion of only gamma-delta T cells (cellular context: ‘‘CD4/
CD8 T cells-T24”) but was significantly reduced if mdPBMC were also depleted of CD4 T cells (CD8 T cells-T24) or CD8 T cells (CD4 T cells-T24). Data shown are the least
squares means and standard deviations for experiments on blood collected from 3 steers. Significance symbols represent P-values adjusted for multiple comparisons to the
condition of maximum killing activity (open bar) such that: *, Padj < 0.05; **, Padj < 0.01; ***, Padj < 0.001.
2022 G.S. Abdellrazeq et al. / Vaccine 38 (2020) 2016–2025
of a bacterium viability assay provided a way to study the mecha-
nisms used for the intracellular killing of Map in infected target
cells [6]. The development of an assay overcame one of the difficul-
ties of studying the immune response to slow growing mycobacte-
rial pathogens. Slow growing bacteria like Map, take six or more
weeks before colonies begin to be detectable when using the col-
ony forming unit assay as a readout to analyze the effector T cell
response that occurs following antigenic stimulation.
Using a Map/DrelA-vaccinated steer, we first used our model
system to dissect the ex vivo recall response to Map/DrelA and
MMP. The studies demonstrated that the main cell subsets prolif-
erating in response to stimulation with Map/DrelA or MMP-
pulsed DC were CD4 and CD8 T cells. The responses were MHC-
restricted. Killing activity was mediated primarily by CD8 T cells
through the perforin-granzyme B pathway [6]. A preliminary CD4
T cell depletion study indicated development of CTL activity was
reduced if CD4 T cells were removed from cultures before stimula-
tion with Ag-pulsed DC [6]. The data provided support for the sup-
position that CD4 T cell help is essential for initiation of a
functional CD8 T cell recall response to Map/DrelA and MMP.
Since CD4 T cell help during priming is often observed for the
generation of a primary CTL response to non-inflammatory targets
in mice, we conducted the present ex vivo study to determine if
this observation was the same in regard to the Map/DrelA and
MMP candidate vaccines. In this study, we found the primary
CD8 CTL responses were significantly diminished in cultures
depleted of CD4 T cells prior to antigenic stimulation by DC. We
also found that CD8 CTL responses were blocked in whole mdPBMC
cultures in the presence of mAbs specific for MHC class I and MHC
class II molecules. Importantly, we observed there was complete
blockade of CD4 and CD8 T cell activation in the presence of mAbs
to either MHC I or MHC II alone. The data presented here provide
evidence that simultaneous cognate CD8 and CD4 T cell recogni-
tion of antigenic peptides presented on MHC I and MHC II mole-
Fig. 6. The effect of anti-MHC antibodies present in mdPBMC during stimulation by MMP on intracellular killing ofMap. (A) Representative scatter plots comparing the effect
of anti-MHC antibodies on the proliferative response to MMP. A selective gate was placed on CD4 or CD8 positive cells for analysis displayed in FSC vs CD45R0 (memory T cell
marker) to identify population of cells proliferating in response to stimulation with MMP. The plots show proliferation is greatly reduced in cultures of cells incubated with
anti-MHC antibodies. Presence of an isotype control specific for an unrelated Ag had no effect on the proliferative response. (B) In comparison to control conditions (leftmost
solid bars), significant killing of Map (reduced live bacteria = higher CT value) was detected after infected MoMU were co-cultured 24-hours with unseparated mdPBMC
stimulated by MMP (open bar). The presence of antibodies to MHC I, MHC II, or both MHC I and MHC II during stimulation of mdPBMC with MMP (rightmost solid bars)
significantly reduced cell proliferation and intracellular killing of Map. Data shown are the least squares means and standard deviations for experiments on blood collected
from 3 steers. Significance symbols represent P-values adjusted for multiple comparisons to the condition of maximum killing activity (open bar) such that: *, Padj < 0.05; **,
Padj < 0.01; ***, Padj < 0.001.
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cules is essential for development of a functional primary CTL
response to MMP.
The importance of CD4 and CD8 T cell cognate antigen recogni-
tion to the development of a functional primary CTL response to a
bovine pathogen was previously demonstrated in one other study
using an ex vivo Theileria parva culture system [38]. In this study, T.
parva-infected lymphocytes, which express MHC class I and class II
molecules, were used as APC, and were cultured in the presence of
T. parva-naïve CD8 T cells, with or without primed CD4 T cells. T.
parva-specific CD8 CTL developed only in cultures that contained
primed CD4 T cells. Furthermore, if the primed CD4 T cells were
cultured in the same plate, but separated from the APC and CD8
T cells by a semi-permeable membrane, no primary CD8 CTL
response to T. parva developed, indicating that direct cell-cell con-
tact between APC, CD4 T cells, and CD8 T cells is required for the
development of a primary CTL response in this system. This study,
like the present study, provides evidence of the importance of
simultaneous cognate antigen recognition by CD4 and CD8 T cells
for the development of a functional CTL response in the cattle.
In summary, analysis of the immune response to a Map/relA
deletion mutant and a candidate peptide-based vaccine for Map
in cattle have provided insight into factors regulating the develop-
ment of CTL to an intracellular pathogen that are of universal
importance. Deletion of relA disrupted the pathways used by Map
to dysregulate the immune response and allowed for the develop-
ment of an immune response that cleared the infection with the
mutant. Analysis of the recall response revealed vaccination led
to development of a CD8 CTL response that targeted a membrane
protein, MMP. Analysis of the entire immune response to MMP
ex vivo revealed simultaneous cognate recognition of antigenic
peptides by CD4 and CD8 T cells, presented by DC pulsed with
MMP is essential for generation of CTL against Map. Blocking of
Ag presentation by mAbs to either MHC I or MHC II molecules
blocked the proliferative and CTL responses to Map. The findings
may have revealed an elusive component of the CTL response to
pathogens. The ex vivo platform developed to conduct the studies
provide an opportunity for further in depth studies in large outbred
animal species like cattle and also humans.
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